Product Details
| Product Name:
L162389 |
CAS No.:
169281-53-2 |
| Purity:
99.68% |
Supply Ability:
10g |
| Release date:
2024/11/20 |
Product Introduction
Bioactivity
| Name | L162389 |
| Description | L162389 is an orally active and potent angiotensin II receptor antagonist with a balanced affinity for AT1 and AT2 receptor subtypes that stimulates the conversion of phosphatidylinositol. |
| In vitro | METHODS: To determine the characteristics of the non-peptide angiotensin AT1 ligand L162389, a series of affinity assay studies were conducted.
RESULTS: L162389 also stimulated phosphatidylinositol turnover, although only a minor fraction of the angiotensin response, acting as an angiotensin antagonist with an IC50 of 105 nM [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | L162389 |
| Inhibitors Related | Tranilast | Enalapril Maleate | Azilsartan Methyl Ester | Sacubitril/Valsartan | Azilsartan | Irbesartan | Losartan | Ramipril | Captopril | Valsartan Methyl Ester |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1428327-31-4
$34.00 / 1mg
-
CAS:2751-68-0
$350.00 / 1mg
-
CAS:58433-11-7
$162.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$333.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-20 |
United States